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Pediatric Endocrinology strives to advance 
the understanding and management of 
endocrine diseases in childhood. Although 
both basic and clinical research have pro-
vided important new insights into many 
endocrine diseases, the mechanisms under-
lying several clinical conditions have not 
yet been elucidated and many new poten-
tial therapeutic interventions remain to 
be tested. It has also become increasingly 
apparent that experiences and exposures 
throughout fetal life and childhood can 
have important effects on many diseases 
that develop much later during adult life. 
Alterations to the endocrine system medi-
ate many of these long-term effects and 
understanding how these changes occur 
and how they translate into compromised 
health in adulthood have become addi-
tional questions that confront pediatric 
endocrinologists.
I will quote only a few examples of the 
grand challenges that wait to be tackled in 
the near future.
There is increasing evidence that the 
hypothalamus is involved in the regulation 
of energy balance and glucose homeostasis 
and, ultimately, in the occurrence of dia-
betes (Elmquist and Marcus, 2003; Prodi 
and Obici, 2006). In humans, however, 
studies on the brain control of metabolism 
and endocrine system are difficult and only 
translational research will provide robust 
data to be translated into clinical practice. 
Although the transfer of information from 
basic to clinical science requires hard work 
and is often disappointing, it is certainly 
worthwhile as shown by the results achieved 
in other disciplines such as Oncology.
For almost a century endocrine research 
has focused on the interaction between hor-
mones and their receptors, providing major 
advances in the understanding of endo-
crine system physiology. More recently, the 
research focus has shifted to the pathways 
downstream from the receptor. The study of 
intracellular hormone signaling has revealed 
that some endocrine diseases may originate 
from alterations of signal  transduction 
(Kofoed et al., 2003). It is easy to foresee 
that further investigations will reveal that 
many yet unexplained endocrinopathies are 
the result of subtle alterations of intracel-
lular signaling.
Novel genes have recently been discov-
ered to play a pivotal role in the regulation 
of reproduction and growth (Weedon and 
Frayling, 2008; Bianco and Kaiser, 2009). 
Genome wide association analysis has 
revealed the influence of many unexpected 
genes in the control of growth, puberty and 
diabetes (Dateki et al., 2008; Zeggini et al., 
2008; Ong et al., 2009). This new large-scale 
genetic approach challenges the research-
ers to obtain more complete descriptions 
of the susceptibility architecture of endo-
crine traits and to translate the informa-
tion gathered into improvements in clinical 
management. However, the mechanisms 
by which genetic information is translated 
into phenotypic features and diseases as 
well as those underlying the interaction 
among hundreds of genes are still largely 
unknown. Genetic manipulation of experi-
mental species, which uses transgenic and 
gene-knockout technology, has led and will 
lead to important advances in determin-
ing the relationship between genes and the 
function of their encoded proteins in the 
intact organism.
Alterations in the embryo-fetal and 
early postnatal hormonal environment, 
caused by either maternal diet or exposure 
to environmental factors, can modify the 
epigenome, and these modifications are 
inherited in somatic daughter cells and 
maintained throughout life, ultimately 
leading to permanent metabolic and endo-
crine changes (Gluckman et al., 2008). We 
are at the beginning of the epigenomics era 
that may provide important insights to be 
translated into interventions to revert epi-
genetic programming. Early prevention of 
adult diseases is nowadays a primary objec-
tive of Pediatrics in general and Pediatric 
Endocrinology in particular. Obesity, dia-
betes, hypertension and cardiovascular 
disease in adulthood may originate during 
 embryo-fetal  development and early post-
natal life (Barker et al., 1989; Robinson 
et al., 1992; Barker, 1995). Therefore, the 
elucidation of environmental, (epi)genetic, 
and endocrine mechanisms leading to long-
term metabolic risk represents a primary 
task of the Pediatric Endocrinologist.
The last two decades have witnessed 
growing concerns over the potential adverse 
effects that may result from exposure to a 
group of chemicals that have the poten-
tial to alter the normal functioning of the 
endocrine system in wildlife and humans. 
Potential adverse outcomes in both wild-
life and humans have focused mainly on 
reproductive and sexual development and 
function, altered immune and nervous sys-
tem, thyroid function and hormone-related 
cancers. Analysis of the human data by itself, 
while generating concerns, has so far failed 
to provide firm evidence of direct causal 
associations between exposure to endocrine 
disruptors and adverse health outcomes. 
Our current understanding of the effects 
posed by endocrine disruptors to humans 
is incomplete. Uncertainty over the possible 
effects of chronic exposures to a number of 
chemicals with endocrine disrupting poten-
tial and the fundamental role played by the 
endocrine system in maintaining homeos-
tasis make the study of the effects posed by 
exposure to these chemicals a worldwide 
research priority.
Further challenges come from the devel-
opment of novel therapeutic approaches 
to endocrine diseases in childhood. New 
drug formulations, individualized treat-
ments based on pharmacogenomics, as 
well as gene and stem cell therapies repre-
sent further research fields for the Pediatric 
Endocrinologist of the 21st century.
Despite the decline in the total number 
of young pediatricians who are choosing 
subspecialties, the demands for pediat-
ric research expertise in all disciplines, 
especially endocrinology, are increas-
ing. American and European Regulatory 
Agencies (Food and Drug Administration, 
FDA, and European Medicines Agency, 
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EMA) now require studies specifically 
designed to investigate pharmacologi-
cal and toxicological aspects in pediatric 
populations, to test efficacy and safety and 
to identify the appropriate dosages and 
formulations. This will therefore be an 
increasing demand that will require the 
expertise of pediatric subspecialists.
RefeRences
Barker, D. J. P. (1995). Fetal origins of coronary heart 
disease. Br. Med. J. 311, 171–174.
Barker, D. J. P., Winter, P. D., Osmond, C., and Margetts, 
B. (1989). Weight in infancy and death from ischaemic 
heart disease. Lancet 2271, 577–580.
Bianco, S. D., and Kaiser, U. B. (2009). The genetic and 
molecular basis of idiopathic hypogonadotropic 
hypogonadism. Nat. Rev. Endocrinol. 5, 569–576.
Dateki, S., Fukami, M., Sato, N., Muroya, K., Adachi, M., 
and Ogata, T. (2008). OTX2 mutation in a patient with 
anophthalmia, short stature, and partial growth hor-
mone deficiency: functional studies using the IRBP, 
HESX1, and POU1F1 promoters. J. Clin. Endocrinol. 
Metab. 93, 3697–3702.
